Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2019.10.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.
Med
September 2025
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200000, China; Academy for Clinical Innovation and Translation of Shanghai, Shanghai 200000, China. Electronic address:
Background: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) with rapidly progressive interstitial lung disease (RPILD) is a fatal disease. Although Janus kinase inhibitors (JAKi) hold their promise in treating MDA5+ DM, regimen for RPILD is still urgently needed to improve the adverse prognosis.
Methods: Based on a large inception cohort of MDA5+ DM, patients with RPILD (oxygen index [OI] < 300 within the first 3 months of disease duration) were included.
Anti-MDA5 antibody dermatomyositis: PET findings of early interstitial lung disease.
Reumatol Clin (Engl Ed)
January 2025
Division of Rheumatology, Immunology, and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.
Ulcerative heliotrope rash in anti-MDA5-positive dermatomyositis.
Rheumatology (Oxford)
September 2025
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Characterization of Muscle Tissue Cell Diversity and Clinical Implications in Idiopathic Inflammatory Myopathy.
J Cachexia Sarcopenia Muscle
October 2025
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Idiopathic inflammatory myopathies (IIMs) exhibit diverse cellular microenvironments in muscle tissues, yet the full spectrum of cell populations and changes remains unclear. This study aimed to characterize cellular heterogeneity, explore cell-cell interactions and assess the prognostic value of cell subtype abundances across IIM subtypes in Han Chinese.
Methods: Muscle samples from six IIMs and three normal controls (NC) underwent single-cell RNA sequencing (scRNA-seq), whereas bulk RNA sequencing was performed on 203 IIMs and 19 NC.